Spike Protein News and Research

RSS

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

In a new study, researchers describe the identification of a neutralizing antibody that binds to the RBD at the same site as the human host cell receptor.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

Sensitivity of coronavirus antibody tests may be lower than stated on the package

A study by University of Tartu researchers indicates that the sensitivity of tests used to detect viral antibodies in a blood sample may differ significantly. The combination of several tests may give the best result.

3 Dec 2020

High seroprevalence of short-lived anti-SARS-CoV-2 antibodies in Paris

A recent study indicates a high seroprevalence of antibodies against SARS-CoV-2 among individuals working in a Paris-based institute.

3 Dec 2020

Designed proteins assemble antibodies into modular nanocages

With cues from nature, designing functional molecules enables scientists to nanoengineer and customize for specific uses.

3 Dec 2020

Nanoparticles with neutralizing antibodies can inactivate SARS-CoV-2

Using nanoparticles conjugated with SARS-CoV-2 neutralizing antibodies, researchers demonstrated that intense local heating could inactivate the virus.

3 Dec 2020

Long-range allosteric influences on SARS-COV-2-ACE2 stability and detachment

The COVID-19 pandemic is caused by SARS-CoV-2, a novel beta-coronavirus which has numerous spike proteins on its membrane.

3 Dec 2020

N-Glycosylation sites may contribute to spike-mediated invasion by SARS-CoV-2

The sugar residues decorating the spike (S) protein of SARS-CoV-2 are essential to the viral-receptor binding.

3 Dec 2020

Pomegranate extract could inhibit the virus that causes COVID-19

Researchers have conducted a study demonstrating the potential antiviral effects of pomegranate extract against SAR-CoV-2.

3 Dec 2020

The UK approves Pfizer vaccine for December 2020 roll out

The UK approves Pfizer vaccine and schedules phased vaccination process, commencing December 2020.

2 Dec 2020

SARS-CoV-2 D614G mutation does not affect performance of serological assays

In a new study published in The Journal of Infectious Diseases, US researchers considered the emergence of a new SARS-CoV-2 spike protein variant. They compared spike G614-based assay to the original D614-based assay – pointing towards the development of recognizable, cross-responsive humoral immunity.

2 Dec 2020

Spanish-originated SARS-CoV-2 variant A222V shows rapid spread in Lazio, Italy

A startling new study reports the rapid rise to dominance of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain in Italy. This strain, termed the GV clade, is characterized by a single point mutation.

2 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

Scientists detect a sarbecovirus phylogenetically related to SARS-CoV-2 from bats in Japan

A team of researchers at the University of Tokyo in Japan have detected a sarbecovirus, called Rc-o319, which is phylogenetically positioned in the same clade as SARS-CoV-2 in Rhinolophus cornutus bats in Japan.

2 Dec 2020

Particulate matter levels can play a significant role in SARS-CoV-2 transmission

A new study has found that particulate matter (PM) plays a role in providing surfaces for SARS-CoV-2 transmission and interaction, enabling fomite transmission through deposition.

2 Dec 2020

SARS-CoV-2 deletion mutations may have attenuated infectivity in some strains

A team of researchers at the University of Hong Kong has identified a panel of SARS-CoV-2 variants, called Del-mut, which contains a deletion in the S1/S2 junction. Upon investigating one of the deleted variants in animal models, they found that Del-mut-1 is attenuated in its ability to cause disease or pathological changes.

2 Dec 2020

Nanomedicine's giant step into the fight against the COVID-19

A recent editorial in Nature Nanotechnology discusses the enormous feat of scientific innovation, with messenger RNA (mRNA)-based vaccines developed to deliver the gene sequence of specific SARS-CoV-2 viral proteins into host cells using nanotechnology platforms.

1 Dec 2020